All Topics
All Topics
Technology
Technology
AI
AI
Business
Business
Entertainment
Entertainment
News
News
Programming
Programming
Science
Science
Design
Design
Environment
Environment
Finance
Finance
Crypto
Crypto
Politics
Politics
Sports
Sports
Education
Education
Gaming
Gaming
Art
Art
Music
Music
Health
Health
Security
Security
Books
Books
Food
Food
Travel
Travel
Personal
Personal
Bluesky
Twitter

A Multicenter, Open-label, Phase II Clinical Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics (PK), and Immunogenicity of the Combination Therapy of SYS6026 in the Treatment of Advanced Solid Tumors

3d agoen
Read on clinicaltrials.gov

From the article

Conditions : Solid Tumor Interventions : Drug: SYS6026 combined with Enlonstobart therapy Sponsors : CSPC Megalith Biopharmaceutical Co.,Ltd. Not yet recruiting
Continue reading on clinicaltrials.gov

You might also wanna read

Comments

Sign in to join the conversation.

No comments yet. Be the first.